Martek Biosciences Corp

Martek Biosciences — Canaccord Genuity Growth Conference 2010

16 slides from Martek Biosciences's conference presentation, Aug 9, 2010

  1. Slide 1: Martek Biosciences Investor Presentation

    Slide 1: Martek Biosciences Investor Presentation

    Martek Biosciences Investor Presentation Canaccord Genuity Growth Conference August 2010

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements 2 Sections of this presentation contain forward-looking statements concerning, among other things, expectations regarding future revenue growth, product introductions, production expansion, capital expenditures and gross margins. These statements are based upon numerous as

  3. Slide 3: Martek Today

    Slide 3: Martek Today

    Martek Today Powerful technology platform and research engine The global leader in microbial DHA and ARA for infant formula Delivering growth – Revenue, gross margin, earnings and cash flow Growing DHA business outside of infant formula Newly acquired growth platform – branded consumer health produc

  4. Slide 4: Martek's Roots

    Slide 4: Martek's Roots

    Martek’s Roots 4 Microbial biotechnology Expertise in modification, optimization, development and production of microbes and microbially-derived products Significant expertise in the development and production of high value products from microbial sources – Primary focus to date on microbial-derived

  5. Slide 5: Martek Research Engine

    Slide 5: Martek Research Engine

    Martek Research Engine 5 Proprietary Platform Unique Microbial Production Systems Comprehensive lab, pilot and production scale manufacturing Capabilities Microbial biology Algal genomics Core Expertise Fermentation and oil processing

  6. Slide 6: Why DHA?

    Slide 6: Why DHA?

    Why DHA? 6 Maternal Health & Outcomes Promotes maternal DHA status Increases DHA content of breast milk Promotes fetal brain and eye development Brain & Eye Development and Function Improves visual acuity Promotes cognitive performance Cardiovascular Heart Health Lowers triglycerides Increases HDL M

  7. Slide 7: Why Martek's DHA?

    Slide 7: Why Martek's DHA?

    Why Martek’s DHA? 7 Source Unique and trusted Contaminant Free Vegetarian Sustainable Science Lifetime benefits Large and growing body of published studies MIDAS / Memory trial Dietary shortfall Consumer Acceptance Used by leading world-wide consumer brands Over 50 million infants have consumed Esta

  8. Slide 8: Base Business – Infant Formula

    Slide 8: Base Business – Infant Formula

    Base Business – Infant Formula 8 Martek DHA/ARA Sales for Infant Formula ($ in millions) Martek licensees represent approximately 75% of the global market International markets now >50% of Martek’s total IF sales 53 million babies worldwide fed IF with Martek DHA/ARA since 1998 Recent extension of g

  9. Slide 9: Growth Strategy

    Slide 9: Growth Strategy

    Growth Strategy 9 Leverage microbial platform beyond DHA and ARA Branded Ingredients Commercialize nutritional health & wellness products Partner pipeline products outside of nutrition Branded consumer health products (Amerifit)

  10. Slide 10: Non-Infant Formula DHA

    Slide 10: Non-Infant Formula DHA

    Non-Infant Formula DHA 11 Non-IF nutritional segment includes life’sDHA sales for use in food, beverage, perinatal, supplement, and animal nutrition applications Does not include Amerifit life’sDHA provides customers with a unique, vegetarian, sustainable and trusted source of DHA omega-3 Pipeline f

  11. Slide 11: Sales by Key Brand – Branded Consumer Health (Amerifit)

    Slide 11: Sales by Key Brand – Branded Consumer Health (Amerifit)

    Sales by Key Brand Branded Consumer Health (Amerifit) Develops, markets and distributes branded consumer health and wellness products Product portfolio of leading brands Culterelle – growing probiotic category AZO – growing UTI category Estroven – leading menopause symptom relief supplement Broad U.

  12. Slide 12: Project Pipeline Overview

    Slide 12: Project Pipeline Overview

    Project Pipeline Overview Project Description Partner Therapeutic Proteins Algal-based protein expression platform Confidential Microbial Biofuels Conversion of sugar into biodiesel through fermentation Seed Oil DHA Oilseed-based production system for DHA High Purity DHA 90+% pure DHA product for th

  13. Slide 13: Recent Developments

    Slide 13: Recent Developments

    Securing the Core IF Business Extension of global sole-source supply agreements Mead Johnson (ARA + DHA through 2015), Danone (ARA through 2014) Others in process Streamlining Operations and Managing the Cost Structure Winchester site restructuring + potential asset sale Lower ARA COGS in CY 2011 Ma

  14. Slide 14: Annual Financial Performance

    Slide 14: Annual Financial Performance

    Revenue ($ millions) Gross Margin *EPS excludes restructuring charges, tax gain; See year-end earnings releases for reconciliation to GAAP EPS. 15 Non-GAAP EPS* Annual Financial Performance FY’10 Revenue Outlook (guidance as of June 3, 2010): Total revenue $440-$445 million (27%-29% Y/Y growth) Non-

  15. Slide 15: Q3'10 Guidance

    Slide 15: Q3'10 Guidance

    Q3’10 Guidance Guidance provided June 3, 2010: Metric Range Total Revenue $113 - $118 million Infant Formula Revenue $76 - $80 million Non-IF Nutritional Revenue $12 - $14 million Contract Manuf. and Services Revenue $2.5 - $3.0 million Gross Margin 49% - 50% EPS $0.33 - $0.36* 16 * Excludes charges

  16. Slide 16: Summary

    Slide 16: Summary

    Powerful technology platform and research engine The global leader in microbial DHA and ARA for infant formula Delivering growth – Revenue, gross margin, earnings and cash flow Growing DHA business outside of infant formula Newly acquired growth platform – branded consumer health products (Amerifit)

Source: SEC EDGAR · 8-K filed Aug 9, 2010

More decks from Martek Biosciences Corp